NuScale Hit by Securities Fraud Class Action Amid Stock Drop, Amplifying Legal and Commercialization Risks

What happened

A securities fraud class action lawsuit has been filed against NuScale Power by law firm Bleichmar Fonti & Auld LLP following a 12% stock drop, alleging violations of federal securities laws. This legal action emerges against a backdrop of severe financial strain, with the DeepValue report noting FY2025 operating cash use of $459.6M against mere $31.5M in revenue, driven by non-binding milestone payments. NuScale's commercialization hinges on converting ENTRA1/TVA agreements into binding PPAs, a process already complicated by Fluor's planned sale of 40M shares in 2Q26 and high cash obligations. The lawsuit adds to existing legal scrutiny, including prior short-seller allegations and a dismissed shareholder suit, potentially eroding investor confidence and hindering capital access. Ultimately, this event underscores the company's vulnerability to both operational delays and external pressures, reinforcing the DeepValue report's cautious 'WAIT' rating.

Implication

The class action could impose legal costs and settlements, further straining NuScale's liquidity as it manages $398M in 2026 cash obligations. Negative sentiment from the lawsuit may deter new investors, worsening the equity overhang from Fluor's share sales and increasing dilution risk. Partner negotiations for binding PPAs might slow if counterparties perceive heightened legal or reputational risks, delaying revenue-generating contracts. Without a binding PPA, NuScale's cash burn persists, raising the probability of additional equity issuance at depressed prices to fund milestones. Consequently, the path to value creation narrows, emphasizing the need for clear progress on financeable contracts to counterbalance these headwinds.

Thesis delta

The DeepValue thesis to wait for a binding PPA and project financing remains intact, but the class action lawsuit introduces additional near-term headwinds. Specifically, it escalates legal and reputational risks, potentially delaying partner engagements and increasing the cost of capital. This reinforces the 'WAIT' stance, as investors should monitor for resolution of legal issues alongside commercial progress before considering entry.